To view the Abstract, just click the link. 

To request a reprint of the paper, click the link "Request Article", and send the Email

To download slides, right-click the link labeled "slides" and "Save Target As" to save the slides to your computer.

To return to the main library, just click "Back

 

TIMI OPUS 16 Articles

Association Between Blood Glucose and Long-Term Mortality in Patients With Acute Coronary Syndromes in the OPUS-TIMI 16 Trial (Am J Cardiol 2006 Jun 1 ;97:1573–1577) 

Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006 May;151(5):976

Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes–Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study (Am Heart J 2006 Feb ;151:338-44.)

Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates Journal of the American College of Cardiology 2005 Jun 7;45:1781– 6

Statin therapy - Time to turn the focus from efficacy to implementation? American Heart Journal 2005 March ;149:381- 3

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS–TIMI 16) trial American Heart Journal 2005 March ;149:444- 50.

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non–ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial American Heart Journal 2005 Feb;149:275-83.

Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16 International Journal of Cardiology 100 (2005) 101– 107

Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes BMC Medical Genetics 2004, 5

Soluble CD40L Risk Prediction After Acute Coronary Syndromes Circulation. 2003 Sep 12;108:1049-1052.

Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes Clinical Chemistry 49, No. 8, 2003 Aug

Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study American Heart Journal; 2003 Apr;145:622-7.

Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes Circulation. 2003 Feb 11 ;107:690-695.

Role of Oral Blockade of Platelet Glycoprotein IIb/IIIa on Neutrophil Activation in Patients with Acute Coronary Syndromes Cardiovascular Drugs and Therapy 17 129–132 2003

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood. 2001 Dec 1;98:3256-3260

The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine 2001 Oct 4 ;345:1014-21.

Association of White Blood Cell Count With Increased Mortality in Acute Myocardial Infarction and Unstable Angina Pectoris The American Journal of Cardiology Vol. 87 March 1, 2001

Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial Circulation. 2000 Jul 11;102:149-156.